Has Rama Kongara received payments from drug or device companies?

Yes. Drug and device makers reported $2,948 in general payments to Rama Kongara across 206 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rama Kongara did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rama Kongara come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rama Kongara

Psychiatry · Baton Rouge, LANPI 1881867448

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.6% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 24.2% of the total. Reporting peaked in 2019 at $1,356 and has fallen 94.8% since, to $70 in 2022.

$2,948in general payments, 2019–2025

Across 206 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sunovion Pharmaceuticals Inc.$713
Takeda Pharmaceuticals U.S.A., Inc.$670
Lundbeck LLC$219
Otsuka America Pharmaceutical, Inc.$209
Neurocrine Biosciences, Inc.$185
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$182
plus $770 from 14 others

What the payments were for

Food & beverage$2,81996%
Education$1294%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sunovion Pharmaceuticals Inc.	48	$713
Takeda Pharmaceuticals U.S.A., Inc.	54	$670
Lundbeck LLC	15	$219
Otsuka America Pharmaceutical, Inc.	12	$209
Neurocrine Biosciences, Inc.	9	$185
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	14	$182
Shire North American Group Inc	17	$171
Bausch Health US, LLC	4	$84
Teva Pharmaceuticals USA, Inc.	6	$79
Vanda Pharmaceuticals Inc.	4	$77
Avanir Pharmaceuticals, Inc.	5	$73
Johnson & Johnson	5	$73
Neos Therapeutics, LP	3	$57
Acadia Pharmaceuticals Inc	3	$46
Eisai Inc.	2	$34
Jazz Pharmaceuticals Inc.	1	$20
Neuronetics, Inc.	1	$15
Adlon Therapeutics L.p.	1	$14
Ironshore Pharmaceuticals Inc.	1	$14
Rhodes Pharmaceuticals L.p.	1	$13

How this compares

$2,948 in reported general payments places this provider in the 80th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fluphenazine Hcl	23	$606

Paid to pharmacies, not to this prescriber.

Other psychiatry in Baton Rouge

Larry WarnerBaton Rouge$495K
Abdul KhanBaton Rouge$156K
Donna FargasonBaton Rouge$11K
Aniedi UdofaBaton Rouge$9K
Sudheera RachamalluBaton Rouge$7K
Jason BoudreauxBaton Rouge$5K
Anupama AtluriBaton Rouge$5K
Patrick HayesLake Charles$837K
Maria CruseThibodaux$522K
Gregory BrownShreveport$495K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →